Combination therapy of interferon-alpha [PDferon and B®] ribavirin for chronic hepatitis C

ABSTRACT

Introduction: the addition of ribavirin [RIBA] to the standard treatment with interferon [IFN] alpha led to an improvement in sustained virologic response [SVR] from less than 20% with IFN monotherapy to 40-45% in combination therapy. The aim of this study is to assess the therapeutic efficacy and safety of IFN alpha [PDferon B®] in combination with RIBA on Iranian patients with chronic hepatitis C [CHC]